Stem cell therapies for cardiovascular disease operate primarily through paracrine signaling rather than direct cell replacement, fundamentally reshaping regenerative medicine approaches. Research demonstrates these therapies work by regulating endothelial repair, modulating vascular smooth muscle cell phenotypic switching, and dampening inflammatory pathways that drive atherosclerosis and vascular aging. This mechanistic understanding has expanded therapeutic options to include endothelial progenitor cells, mesenchymal stromal cells, and engineered extracellular vesicle platforms. The paradigm shift represents a major evolution in cardiovascular regenerative medicine, moving away from the original concept of simply replacing damaged cells toward orchestrating complex tissue repair processes. For adults facing cardiovascular disease, this opens pathways to treatments that could restore arterial function rather than merely managing symptoms. The integration of biomaterials, gene editing, and metabolic reprogramming further enhances therapeutic potential. However, this remains largely preclinical work requiring extensive human trials to validate safety and efficacy. While promising for future vascular health interventions, the complexity of paracrine mechanisms and individual patient variability present significant translational challenges before these therapies reach clinical practice.